Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives

Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives

Glioblastomas are aggressive, fast-growing primary brain tumors. After standard-of-care treatment with radiation in combination with temozolomide, the overall prognosis of newly diagnosed patients remains poor, with a 2-year survival rate of less than 20%. The remarkable survival benefit gained with...

Full description

Bibliographic Details
Main Authors: Bas Weenink, Pim J. French, Peter A.E. Sillevis Smitt, Reno Debets, Marjolein Geurts
Format: Article
Language:English
Published: MDPI AG 2020-03-01
Series:Cancers
Subjects:
adoptive t cell therapy
antigens
checkpoint inhibitors
clinical studies
glioblastoma
immune privilege
tumor micro-environment
vaccines
Online Access:https://www.mdpi.com/2072-6694/12/3/751

Internet

https://www.mdpi.com/2072-6694/12/3/751

Similar Items